King Fahad Medical City, Boston Oncology Sign Agreement to Advance Immunotherapy Manufacturing

King Fahad Medical City and Boston Oncology have signed an agreement to establish an advanced manufacturing unit to produce immunotherapy with programmed T cells using a clean closed system on the sidelines of the 7th Global Health Exhibition, held from October 21 to 23 at the Riyadh Exhibition and Convention Center in Malham, north of Riyadh.
 The agreement aims to attain self-sufficiency in producing advanced immunotherapies, encourage investment in the health sector, particularly in the pharmaceutical and therapeutic fields, foster medical and technical innovation and drive the localization of advanced medical technologies to enhance the efficiency of health services provided to beneficiaries.
 This agreement is in line with the Ministry of Health's endeavour to realize the objectives of Vision 2030 and elevate the Kingdom's status as a regional hub for innovative healthcare.